Therapeutics targeting IGFBP7 for the treatment or prevention of heart failure and metabolic diseases
US10865412B2 · kind B2 · utility
0Cited by
0References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 3, 2017 |
| Grant date | Dec 15, 2020 |
| Priority date | — |
| Expiry date | Nov 3, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/4745
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Insulin-like growth factor-binding protein 7 (IGFBP7) has been identified herein as a therapeutic target for the treatment or prevention of heart diseases, metabolic diseases, and other related disease or conditions. IGFBP7 inhibitors having IGFBP7 expression and/or activity reducing properties are described herein. Treatment methods, and uses, relating to such IGFBP7 inhibitors for the treatment or prevention of heart failure, IGFBP7-related metabolic diseases, and related diseases or conditions are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.